Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 14

Effect of Disease Severity on the Quality of Life and Sense of Stigmatization in Psoriatics

Authors Kowalewska B, Jankowiak B, Cybulski M, Krajewska-Kułak E, Khvorik DF

Received 12 October 2020

Accepted for publication 5 January 2021

Published 2 February 2021 Volume 2021:14 Pages 107—121

DOI https://doi.org/10.2147/CCID.S286312

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Jeffrey Weinberg


Beata Kowalewska,1 Barbara Jankowiak,1 Mateusz Cybulski,1 Elżbieta Krajewska-Kułak,1 Dzmitry Fiodaravich Khvorik2

1Department of Integrated Medical Care, Medical University of Bialystok, Bialystok, Poland; 2Department of Dermatovenerology, Medical University in Grodno, Grodno, Belarus

Correspondence: Beata Kowalewska
Department of Integrated Medical Care, Medical University of Bialystok, 7A Curie-Skłodowskiej Str., Bialystok, 15-096, Poland
Tel +48 85 748 55 28
Email beata.kowalewska@umb.edu.pl

Introduction: Psoriasis is a chronic inflammatory disease of the skin having a profound effect on the quality of life and contributing to the sense of stigmatization in the affected patients. The aim of this study was to analyze the effect of psoriasis severity on the quality of life and sense of stigmatization in psoriatics and to investigate relationships between these measures and sociodemographic variables.
Patients and Methods: The study included 111 patients with psoriasis. The inclusion criteria of the study were the diagnosis of psoriasis and written informed consent to participate. The study was based on a short survey prepared by the authors and four validated scales: Dermatology Life Quality Index (DLQI), 6-item Stigmatization Scale, 33-item Feelings of Stigmatization Questionnaire, and Psoriasis Area and Severity Index (PASI).
Results: Mean PASI score for the study group was 14 pts. Most respondents presented with low DLQI scores, with the mean value of 10.8 pts suggesting that the disease-related ailments were not extremely burdensome for the majority of the patients. Mean stigmatization scores for the 6- and 33-item scale were 7– 8 and 81– 82 pts, respectively.
Conclusion: The severity of psoriasis was the strongest determinant of the quality of life measured with the DLQI. Also, the levels of stigmatization determined with the 6- and 33-item scale correlated significantly with PASI scores.

Keywords: psoriasis, quality of life, stigmatization, psoriasis severity, psychodermatology, DLQI, PASI

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]